Author

Y. Shi

Observed names: Shi Y, Y Shi, Yanpei Shi

Institution: Jingchu University of Technology

Observed institutions: Guangzhou University of Chinese Medicine, Guangxi Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Medical University Cancer Institute and Hospital, Soochow University, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Jingchu University of Technology, Cancer Hospital of Chinese Academy of Medical Sciences, First Affiliated Hospital Zhejiang University, Suzhou University, Zhejiang University

ORCID: 0009-0008-2421-0981

Observed ORCID: 0009-0008-2421-0981

OpenAlex ID: A5110194836

Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer.

2000 · H Kinoshita, Y Shi, et al. · PubMed · 194

The interleukin-10-1082 promoter polymorphism and cancer risk: a meta-analysis

2011 · J. Wang, Q. Ding, et al. · Mutagenesis · 30

A Simple and Rapid Method for the Determination of Pennogenin Diglycoside in Rat Plasma by HPLC-MS: Application to the Pharmacokinetics of the Extract in Gongxuening Capsules

2009 · Q. Liu, Y. Shi, et al. · Journal of Chromatographic Science · 7

P1.01-37 BPI-9016M, a Novel c-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results from a First-In-Human, Phase 1, Dose-Escalation Study

2018 · X. Hu, X. Zheng, et al. · Journal of Thoracic Oncology · 1

Pair of indole-anthraquinone and imidazole structural matrices to design FGF-4 inhibitors in nonalcoholic fatty liver disease

2025 · Yanpei Shi, Xinyang Cao, et al. · International Conference on Biomedical and Intelligent Systems (IC-BIS)

Mechanism of action of Scrofula ointment on gastric cancer based on network pharmacology study

2025 · Sitong Yin, Dan Yin, et al. · International Conference on Bioinformatics and Intelligent Computing (BIC)

844TiP Orelabrutinib combined with rituximab for the treatment of elderly patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL) under the guidance of genetic subtype: A prospective, multicenter, single-arm, response-adaptive clinical study (Origin)

2024 · W. Xie, X. Zheng, et al. · Annals of Oncology

1602P CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results

2024 · K. Li, J. Guo, et al. · Annals of Oncology

[Bioinformatics analysis and prokaryotic expression of Strongyloides stercoralis serine protease inhibitor 1].

2023 · X Han, X Bi, et al. · PubMed

Fish Consumption and Multiple Health Outcomes: An Umbrella Review of Meta-Analyses of Observational and Clinical Studies

2021 · Zhao H, Wang M, et al. · World journal of gastroenterology, hepatology and endoscopy

BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study

2018 · X. Hu, X. Zheng, et al. · Annals of Oncology

Effect of clinical pathways in health education of maintenance hemodialysis patients

2007 · Y. Shi · Medical Journal of West China

[Study on cellular proliferation activity of placental site trophoblastic tumor].

1996 · X Xie, Y Shi, et al. · PubMed

Works count: 13

Citation count: 232

H-index: 3

I10-index: 2